Document is current

Article History

Received: 9 May 2022

Accepted: 2 August 2022

First Online: 19 August 2022

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Informed consent was obtained from the individual described in this publication.

: A. M. Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene/Cardiff oncology, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. A. M. Z. participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Cardiff Oncology, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, and Tyme. A. M. Z. served on clinical trial committees for Novartis, Abbvie, Geron, and Celgene/BMS. A. M. Z. received travel support for meetings from Pfizer, Novartis, and Cardiff Oncology. N. A. P. received consulting fees from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene/Bristol-Myers Squibb, CTI BioPharma, PharmaEssentia, Constellation Pharmaceuticals, and AbbVie; other financial support for serving on an Independent Data Review Committee for Cogent Biosciences. R. M. S. participated in advisory boards and/or had a consultancy with and received honoraria from Bristol Myers Squibb and Gilead Sciences, Inc. All other authors have nothing to disclose. None of these relationships was related to the development of this work. Other authors have nothing to disclose.